Form 4: Director Alister Cowan Increases Stake in Chemours

Chemours Company Director Alister Cowan acquired 7,182 stock units as part of board compensation.

Summary

• Director Alister Cowan acquired 7,182 stock units of The Chemours Company (CC).
• The transaction occurred on May 6, 2026.
• The units were acquired at a price of $0, representing equity-based compensation.
• Following this transaction, the director's total beneficial ownership increased to 43,881.0397 shares.
• The acquired units will convert one-for-one into common stock upon the director's separation from the Board.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of market impact.

Positives

• Director demonstrates alignment with shareholder interests through increased equity holdings.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

The acquired stock units are scheduled to convert to common stock upon the director's eventual separation from the Board.

Industry Context

StockSavvy.ai notes that director equity grants are standard corporate governance practices designed to align board member incentives with long-term shareholder value creation.

Comparison to Industry Standards

• The acquisition of stock units as board compensation is consistent with standard practices for S&P 500 and chemical industry companies.

Stakeholder Impact

• Increased alignment between the Board of Directors and shareholders.

Next Steps

• Conversion of stock units to common stock upon the director's future departure from the Board.

Key Dates

Keywords

Chemours, CC, Insider Trading, Director Compensation, Equity Ownership